Logo image
Integrated brain tumor segmentation and MGMT promoter methylation status classification from multimodal MRI data using deep learning
Journal article   Open access   Peer reviewed

Integrated brain tumor segmentation and MGMT promoter methylation status classification from multimodal MRI data using deep learning

Muhammad Sohaib Iqbal, Usama Ijaz Bajwa, Rehan Raza and Muhammad Waqas Anwar
Digital health, Vol.11, pp.1-27
2025
PMID: 40190333
pdf
Published2.65 MBDownloadView
CC BY-NC-ND V4.0 Open Access

Abstract

Health Care Sciences & Services Health Policy & Services Life Sciences & Biomedicine Medical Informatics Public, Environmental & Occupational Health Science & Technology
Objective Glioblastoma multiforme (GBM) is the most aggressive and prevalent type of brain tumor, with a median survival time of approximately 15 months despite treatment advancements. Determining the O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter status, specifically its methylation, is crucial for treatment planning as it provides valuable prognostic information and indicates chemosensitivity. However, current methods require invasive tissue sampling and genetic testing, resulting in time-consuming processes. The non-invasive technique of assessing MGMT status in GBM patients may offer valuable insights to neuro-oncologists, aiding in precise treatment and surgical planning. Methods This research study utilizes two benchmark datasets—BraTS2021 brain tumor segmentation dataset and MGMT promoter status classification dataset—and proposes a pipeline of segmentation-based classification of MGMT promoter status utilizing all modalities of magnetic resonance imaging (MRI) scans by stacking them. The pipeline consists of two phases: in the first phase, a 3D Residual U-Net (3D ResU-Net) architecture is used to segment the brain tumor into sub-regions using a stack of MRI modalities. In the second phase, the segmented tumor voxel obtained from the first phase is input into a 3D ResNet10 model to predict MGMT promoter status. Results The segmentation phase of the pipeline achieves promising results with average dice scores of 0.81, 0.84, and 0.80 for tumor core (TC), whole tumor (WT), and enhancing tumor (ET) regions, respectively, on the internal validation set. The classification phase obtains a ROC–AUC score of 0.66 on the internal validation set. Conclusion This pipeline demonstrates the potential of a non-invasive approach to support neuro-oncologists in brain tumor diagnosis and treatment planning. While still at the research stage, it provides insights into tumor sub-regions and MGMT promoter status, highlighting the role of AI-driven methods in assessing molecular data. Future studies and clinical validation are needed to further explore its applicability in real-world clinical settings.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

undefined
#3 Good Health and Well-Being

Metrics

1 File views/ downloads
31 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.104 Virology - General
1.104.2810 AI in COVID-19
Web Of Science research areas
Health Care Sciences & Services
Health Policy & Services
Medical Informatics
Public, Environmental & Occupational Health
ESI research areas
Clinical Medicine
Logo image